ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$19.49 USD
+0.20 (1.04%)
Updated Sep 25, 2024 03:59 PM ET
After-Market: $19.49 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Brokerage Reports
ADMA Biologics Inc [ADMA]
Reports for Purchase
Showing records 1 - 20 ( 75 total )
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Vast Top- and Bottom-Line Beat; Another Guidance Bump; Raising PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Beat and Raise Theme Continues After Strong 1Q24; Raising PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Strong Fundamentals and Accelerating Growth Ahead; Raising PT to $7.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Another Beat and Raise Quarter; 2023 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Preliminary 4Q23 Revenue Announced; Guidance Raised; Raising PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
BIVIGAM Receives Pediatric Setting Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Another Plasma Collection Center Wins FDA Authorization; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Record Revenue; Initial Profitability Reached; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Growth Continues to Beat Estimates; 2Q23 Financials; Raising PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Positive EBITDA Achieved; 1Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Meaningful Growth Expected in 2023; 2022 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Another Plasma Collection Center Licensed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Preliminary 4Q22 Revenues; 2023 Guidance Released; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Revenue Guidance Increased; Raising PT to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Top Line Revenue Beat; 3Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
2Q22 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Revenue Growth Expected; Long-Term Trajectory Adjusted; Lowering PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Termination of Coverage-Research Prioritization
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: Research Department
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
VanRx SA25 Aseptic Fill-and-Finish Machine Gets FDA Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R